Pressure Targeted High Flow for Premature Birth

(NeoMATCH Trial)

This trial explores a new method to assist premature babies with breathing, called Pressure Targeted High Flow (PTHF). The researchers aim to determine if PTHF is as effective as the usual breathing support, Continuous Positive Airway Pressure (CPAP), and to assess its impact on the babies' comfort and the workload for hospital staff. Babies in the trial will spend one day on PTHF and another on CPAP, with their breathing and comfort closely monitored. Premature babies born between 24 and 32 weeks, who are more than a week old and weigh at least 1,000 grams, may qualify for this trial. As a Phase 2 trial, this research measures how well PTHF works in an initial, smaller group of premature babies.

The trial information does not specify whether participants need to stop taking their current medications.

Previous studies have used high-flow nasal therapy, similar to Pressure Targeted High Flow (PTHF), to assist preterm babies with breathing. Research has shown that this therapy might reduce the risk of issues like a collapsed lung and nose injuries compared to other treatments. However, it may not always be as effective as methods like CPAP in preventing the need for additional treatment.

For infants, this therapy has generally been well-tolerated, with no major safety concerns reported. Some infants might still require extra assistance, indicating that while the therapy is relatively safe, its effectiveness can vary.

Researchers are excited about the Pressure Targeted High Flow (PTHF) technique because it offers a new way to support the breathing of premature infants. Unlike traditional Continuous Positive Airway Pressure (CPAP), which provides a steady level of pressure, PTHF dynamically adjusts the airflow pressure. This tailored approach could potentially improve comfort and efficiency in delivering oxygen to fragile neonatal lungs. By comparing PTHF first versus CPAP first, researchers aim to find out if this new method can enhance respiratory support and reduce complications in premature babies.

Research has shown that Pressure Targeted High Flow (PTHF) can effectively help premature babies breathe. Studies have found that high-flow nasal cannulas, a type of PTHF, stabilize most preterm babies immediately after birth, with 86% successfully stabilized in the delivery room. Although some cases did not respond to this treatment, high-flow nasal therapy typically causes less nasal damage than Continuous Positive Airway Pressure (CPAP). Additionally, high-flow methods might reduce the need for more invasive treatments like mechanical ventilation. In this trial, participants will start with either PTHF before CPAP or CPAP before PTHF. While CPAP is often recommended for very premature infants, high-flow therapy is gaining recognition as a helpful alternative.¹³⁵⁶⁷